Semastar vs Ozempic: Comparison Guide

Semastar vs Ozempic: Comparison Guide

The conversation around medications for managing type 2 diabetes and supporting weight loss has grown significantly, with names like Ozempic becoming widely recognized. In India, another name, Semastar, has joined the discussion. If you're trying to understand the difference between these two, you're not alone. This guide offers a clear, practical comparison to help you have a more informed conversation with your doctor.

Navigating health decisions requires clear information and professional guidance. Consult your healthcare provider before starting any medication. This article is for informational purposes only and does not constitute medical advice.

What is Semaglutide? The Shared Active Ingredient

At the heart of both Semastar and Ozempic is the same active pharmaceutical ingredient: semaglutide. Understanding semaglutide is the first step to understanding both medications.

Semaglutide belongs to a class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists. In simple terms, it works by mimicking a natural hormone in your body that is released after you eat. This has a few key effects:

• It helps the pancreas release the right amount of insulin when blood sugar is high, which is crucial for managing type 2 diabetes.
• It slows down gastric emptying, which means food leaves your stomach more slowly. This can help you feel full for a longer period.
• It acts on the brain to reduce appetite and signal a feeling of fullness.

Because of these effects, semaglutide has been shown to be effective in improving blood sugar control and can also lead to weight loss.

Introducing the Brands: Ozempic and Semastar

While they share an active ingredient, Ozempic and Semastar are different brands from different manufacturers. This is the primary distinction between them.

Ozempic

Ozempic is the brand name for semaglutide developed and marketed globally by the Danish pharmaceutical company Novo Nordisk. It was one of the first semaglutide products to receive widespread approval and has been the subject of extensive global clinical trials for its use in type 2 diabetes. Its effects on weight loss, observed in these trials, have made it well-known worldwide.

Semastar

Semastar is a semaglutide brand name that Medical Dialogues listed in March 2026 among the brands expected from Torrent Pharmaceuticals after the semaglutide patent expired in India on March 20, 2026. (Sun Pharma's semaglutide brands are Noveltreat and Sematrinity, and Torrent launched its semaglutide as Sembolic and Semalix.) As of October 2026 we could not find an official launch announcement for Semastar confirming its approved use, strengths or device, so ask your doctor or pharmacist to confirm these from the pack. It is described as containing the same active drug, semaglutide, as Ozempic.

Key Comparison Points

When you look closer, the differences and similarities become clearer. Here’s a breakdown of what you should know.

Active Ingredient and Efficacy

As we've covered, this is the most important similarity. Both medications contain semaglutide. Therefore, from a pharmacological perspective, they are designed to produce the same biological effects in the body. The efficacy in controlling blood sugar and the potential for weight loss are tied to this shared ingredient.

Formulation and Delivery

Ozempic is a once-weekly subcutaneous (under the skin) injection given with a pre-filled pen. Indian semaglutide brands come in different formats, including disposable pens, reusable pens, vials and, for some brands, tablets, so check which format Semastar comes in and ask your pharmacist to show you how to use it.

Approved Indications in India

In India, the Central Drugs Standard Control Organisation (CDSCO) is responsible for approving medications. Ozempic is marketed in India for adults with type 2 diabetes to improve glycaemic control. Some other semaglutide products in India (such as Wegovy and some Indian brands) are approved for weight management, so the approved use depends on the specific brand. Your doctor will determine if it is an appropriate treatment for your specific health needs based on the approved guidelines and your overall health profile.

Clinical Data and Research

This is a significant point of difference. Ozempic, being the innovator brand with a longer history on the global market, is backed by a vast body of large-scale, long-term international clinical studies, such as the SUSTAIN trial program. This research is widely published and has been reviewed by regulatory bodies across the world.

Indian semaglutide brands are approved by the Central Drugs Standard Control Organisation (CDSCO), and several manufacturers have reported Phase 3 trials in Indian patients. We could not find published trial data specific to Semastar. The volume of published, long-term global data is naturally more extensive for Ozempic.

Availability and Sourcing

Ozempic is an international brand marketed in India by Novo Nordisk. Semastar is listed as an Indian company's brand. Availability of each can vary by city and pharmacy.

Understanding Potential Side Effects

Because they contain the same active ingredient, the potential side effects of Semastar and Ozempic are expected to be the same. The most commonly reported side effects are gastrointestinal in nature and include:

• Nausea
• Vomiting
• Diarrhoea
• Abdominal pain
• Constipation

These side effects are often more noticeable when first starting the medication or after a dose increase, and they tend to decrease over time for many people. It is essential to discuss your full medical history with your doctor, as GLP-1 medications are not suitable for everyone.

Seek urgent medical help for severe stomach pain that does not go away (it may spread to your back), signs of a serious allergic reaction, or vomiting so much that you cannot keep fluids down. Low blood sugar is more likely if you also take insulin or a sulfonylurea, and people with diabetic eye disease should report any vision changes. Semaglutide is not used in pregnancy, and you should not use it if you or a family member has had medullary thyroid cancer or you have MEN 2. Tell your doctor or anaesthetist that you take it before any surgery or sedation.

Making an Informed Decision with Your Doctor

Choosing a medication is a decision that should only be made in partnership with a qualified healthcare professional. They can provide personalised guidance that an article cannot.

Factors your doctor will consider include:

• Your specific health condition and treatment goals.
• Your complete medical history, including any other conditions you may have.
• Other medications you are currently taking.
• Your lifestyle and personal preferences.

The decision between Ozempic and Semastar, or whether to use semaglutide at all, is a medical one. Your doctor is the best person to help you weigh the benefits and risks for your individual situation. Consult your healthcare provider before starting any medication.

A Summary of the Facts

In essence, Ozempic and Semastar are two different brands of the same medication, semaglutide. Ozempic is the globally recognized innovator product, while Semastar is listed as a brand from an Indian pharmaceutical company. They share the same mechanism of action and potential side effects. The key differences lie in their manufacturer, brand history, and the scale of their supporting clinical trial data.

Ultimately, the most important step is to have an open and honest conversation with your doctor. They can help you understand your options and create a safe and effective treatment plan tailored just for you.

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf
• https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
• https://medlineplus.gov/druginfo/meds/a618008.html
• https://medicaldialogues.in/news/industry/pharma/indias-semaglutide-market-set-for-generic-boom-as-patents-expire-over-50-brands-lined-up-for-launch-see-full-list-165838
• https://cdsco.gov.in/opencms/opencms/en/Home/
• https://www.torrentpharma.com/docs/Press_Release_a634006544.pdf
• https://sunpharma.com/wp-content/uploads/2026/03/SEintimationPRforSemaglutide.pdf